Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.

Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO.

Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010.

2.

The role of EZH2 in tumour progression.

Chang CJ, Hung MC.

Br J Cancer. 2012 Jan 17;106(2):243-7. doi: 10.1038/bjc.2011.551. Epub 2011 Dec 20. Review.

3.

EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ.

Cancer Res. 2012 Jan 1;72(1):315-24. doi: 10.1158/0008-5472.CAN-11-0961. Epub 2011 Nov 8.

4.

Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma.

Balogh Z, Szemlaky Z, Szendroi M, Antal I, Pápai Z, Fónyad L, Papp G, Changchien YC, Sápi Z.

Diagn Pathol. 2011 Nov 3;6:107. doi: 10.1186/1746-1596-6-107.

5.

Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.

Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM.

Oncotarget. 2011 Sep;2(9):669-83.

6.

Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.

Ciarapica R, Miele L, Giordano A, Locatelli F, Rota R.

BMC Med. 2011 May 25;9:63. doi: 10.1186/1741-7015-9-63. Review.

7.

High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas.

Yamaga K, Osaki M, Kidani K, Shomori K, Yoshida H, Ito H.

Mol Med Rep. 2008 Sep-Oct;1(5):633-9. doi: 10.3892/mmr_00000004.

PMID:
21479461
8.

Aberrations of EZH2 in cancer.

Chase A, Cross NC.

Clin Cancer Res. 2011 May 1;17(9):2613-8. doi: 10.1158/1078-0432.CCR-10-2156. Epub 2011 Mar 2. Review.

9.

EZH2 Y641 mutations in follicular lymphoma.

Bödör C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, Calaminici M, Clear A, Iqbal S, Quentmeier H, Drexler HG, Montoto S, Lister AT, Gribben JG, Matolcsy A, Fitzgibbon J.

Leukemia. 2011 Apr;25(4):726-9. doi: 10.1038/leu.2010.311. Epub 2011 Jan 14. No abstract available.

PMID:
21233829
10.

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.

Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC.

Cancer Cell. 2011 Jan 18;19(1):86-100. doi: 10.1016/j.ccr.2010.10.035. Epub 2011 Jan 6.

11.

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA.

Blood. 2011 Feb 24;117(8):2451-9. doi: 10.1182/blood-2010-11-321208. Epub 2010 Dec 29.

12.

Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type.

Nakayama R, Mitani S, Nakagawa T, Hasegawa T, Kawai A, Morioka H, Yabe H, Toyama Y, Ogose A, Toguchida J, Nakayama T, Yoshida T, Ichikawa H.

Am J Surg Pathol. 2010 Nov;34(11):1599-607. doi: 10.1097/PAS.0b013e3181f7ce2c.

PMID:
20975339
13.

High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.

Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX, Xie D.

Mol Med. 2011 Jan-Feb;17(1-2):12-20. doi: 10.2119/molmed.2010.00103. Epub 2010 Sep 10.

14.

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.

Sauvageau M, Sauvageau G.

Cell Stem Cell. 2010 Sep 3;7(3):299-313. doi: 10.1016/j.stem.2010.08.002. Review.

15.

Polycomb group proteins set the stage for early lineage commitment.

Surface LE, Thornton SR, Boyer LA.

Cell Stem Cell. 2010 Sep 3;7(3):288-98. doi: 10.1016/j.stem.2010.08.004. Review.

16.

Synovial sarcoma is a stem cell malignancy.

Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K.

Stem Cells. 2010 Jul;28(7):1119-31. doi: 10.1002/stem.452.

17.

Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma.

He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY, Zeng YX, Xie D.

BMC Cancer. 2009 Dec 22;9:461. doi: 10.1186/1471-2407-9-461.

18.

Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression.

Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q.

Cell Death Differ. 2010 May;17(5):801-10. doi: 10.1038/cdd.2009.162. Epub 2009 Nov 6.

19.

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.

Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5324-9. doi: 10.1073/pnas.0810759106. Epub 2009 Mar 16.

20.

Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.

Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A.

Cell Cycle. 2009 Jan 1;8(1):172-5. Epub 2009 Jan 30. No abstract available.

PMID:
19106613

Supplemental Content

Support Center